The Medical University of South Carolina (MUSC) in the US is set to expand its present cellular therapy programmes and establish an integrated centre.
The initiative is approved by the MUSC board of trustees on 13 December.
Go deeper with GlobalData
MUSC’s new Integrated Center for Cellular Therapy (ICCT) will enhance the synergy between research and clinical practice.
It will be led by ICCT advanced cell therapy scientific director Hongjun Wang, and ICCT immunotherapy and oncology scientific director Shikhar Mehrotra.
The centre also aims to build additional infrastructure to foster industry-sponsored clinical trials, benefiting patients and the wider South Carolina community.
The current facility is the sole accredited cellular therapy centre in South Carolina, providing treatment options for conditions like diabetes, cancer, and sickle cell disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMUSC Health CEO Patrick Cawley said: “This integrated centre is fundamental to what we do at MUSC, bridging the gap between basic science and clinical practice. By developing a next-level, cohesive programmatic structure, the ICCT will be able to more seamlessly integrate research and clinical delivery.
“These therapies will enable MUSC to push the limits of innovation by offering groundbreaking therapies that harness the body’s own immune system and cells to treat or cure diseases while simultaneously protecting healthy tissues, resulting in enhanced patient outcomes.”
MUSC Hollings Cancer Center director Raymond DuBois said: “Facilities like the MUSC Integrated Centre for Cellular Therapy will truly transform health care by accelerating research and treatment at an extraordinary rate.”
The initiative will involve a new facility construction at Cannon Place Park, with the opening targeted for early 2027.
The programme’s growth is set to extend services throughout the MUSC Regional Health Network and its affiliates.
It will also triple the number of existing certified suites and double the faculty involved in research, thereby enhancing treatment capabilities.
